Summary

Overview
Global Pharmaceutical Glass Packaging Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Glass packaging is extensively used in the pharmaceutical industry due to its nonreactive nature and resistance to temperatures. The shelf life of the product and its safety are important in the pharmaceutical industry and hence glass packaging is always preferred to safeguard the contents from oxidation and other reactions to prevent cross-contamination.
Glass packaging enhances the storage time and delivery of drugs which maintains the efficiency of the drug after a few days without any harmful effects. Due to the increasing access to healthcare costs, the demand for generic medicines has increased drastically due to the low costs. hence, the generic drug manufacturers will rely on glass packaging companies for bulk production.
Dynamics
Growing use of generic drugs among people
The increase in healthcare costs led to the increase in the production of generic drugs due to the lower cost. The demand for these drugs is increasing among people as access to healthcare becomes easy.
According to the US Food and Drug Administration, 9 out of 10 prescriptions filled are for generic drugs in the United States. This is because of the high costs associated with drugs. The increasing availability of generic drugs gives rise to competition in the industry. These budding generic drug manufacturers need assistance in packaging their products. Here comes the pharmaceutical glass packaging companies that provide glass vials, ampoules, syringes, etc for filling the generic drug product.
Governments of developing countries are focusing on the reduction of healthcare costs by boosting the production of generic drugs to keep up the demand for generic drugs in the industry which generics represent less than 2% of all healthcare spending worldwide that indicates the low cost of the medicines when compared to the prescription drugs.
High Logistics Cost
Plastic and other materials are easy to transport when compared to glass as they are more fragile. Glass packaging transportation is risky and requires special packaging which costs more than normal packaging. Glass is often heavier than plastic or metal hence, costs more for transport in supply chains. The low weight plastics are always preferred during transportation to cut costs but high-end biosimilars need very expensive glass packaging.
Segment Analysis
The pharmaceutical glass packaging is segmented based on product, drug type, application and region.
The Vials Segment Accounted for Approximately 45.5% of the Market Share
Vials are expected to hold the largest share in the market due to the rising demand for vaccines and other drugs. Parenteral route drugs are often packed in vials which are highly in demand due to its quick action on the target. Launch of the glass vials by glass packaging companies by collaborating with different pharmaceutical companies are driving the market. For instance, in March 2022, SGD Pharma launched ready-to-use sterile 100ml molded glass vials using SG EZ-fill packaging technology.
Furthermore, in July 2023, Corning Incorporated launched Corning Viridian Vials to expand its glass packaging portfolio. The new technology can improve filling-line efficiency by up to 50% while reducing vial-manufacturing carbon dioxide equivalent (CO2e) emissions by up to 30%.
In October 2023, West Pharmaceutical Services, Inc. collaborated with Corning Incorporated for the launch of the first product. The company holds the distribution rights for Corning Valor Glass vials.
Geographical Analysis
North America accounted for Approximately 41.6% of the Market Share in 2022
North America is expected to hold the largest market share due to an increase in demand for generics and total savings as of 2022. For instance, according to the Association for Accessible Medicines, 2023, generic and biosimilar drugs generate $408 billion in savings for America’s patients and health-care system, including employers and taxpayers in 2022.
More than 90 percent of prescriptions were filled in 2022 with generic or biosimilar medicines, but they accounted for less than 18 percent of total prescription drug spending and less than 2 percent of total U.S. healthcare spending. These biosimilars are often packed in glass bottles to prevent unwanted drug reactions.
The demand for glass packaging companies in North America keeps up with the demand of generic drugs sold in this region. The glass packaging which includes vials, ampoules, and syringes is in high demand after the pandemic hit the world due to the usage of vaccines and other drugs.
COVID-19 Impact Analysis
Covid 19 hurt the pharmaceutical glass packaging market due to the stoppage of services such as manufacturing and production which has led to a shortage of drugs and medicines. The workforce and infrastructure have been disrupted due to the increase in the contraction of infection and the implementation of lockdowns worldwide. The healthcare and pharmaceutical sectors were not stable during the peak of covid 19.
By Product
• Vials
• Bottles
• Cartridges and Syringes
• Ampoules
• Others
By Drug Type
• Generic
• Branded
• Biologic
By Application
• Biopharmaceutical companies
• Biotechnology companies
• Research Organizations
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In March 2023, Schott launched the production of amber pharma glass in India to meet the increasing demand for pharmaceutical glass bottles.
• In November 2023, SGD Pharma launched a new glass bottle in its NOVA range which approximately 20% reduction in CO2 emissions compared with the standard heavy glass bottles.
• In June 2023, Corning Incorporated launched a venture that includes the opening of new glass tubing facility to expand its glass packaging portfolio in India.
• In October 2023, SCHOTT AG launched FIOLAX Pro glass tubing with green energy and significantly reduced the Product Carbon Footprint (PCF).
Competitive Landscape
The major global players in the pharmaceutical glass packaging market include Gerresheimer AG, Stevanato Group., NIPRO Corporation., SGD SA., Alphial S.r.l., Bormioli Pharma S.p.A., Ardagh Group, Beatson Clark, Vitro SAB, Stoelzle Glass Group. among others.
Why Purchase the Report?
To visualize the global pharmaceutical glass packaging market based on product type, drug type, application and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pharmaceutical glass packaging market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global pharmaceutical glass packaging market report would provide approximately 58 tables, 65 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Drug Type
3.3. Snippet by Application
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing use of generic drugs among people
4.1.2. Restraints
4.1.2.1. High Logistics Cost
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Production Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Vials*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bottles
7.4. Cartridges and Syringes
7.5. Ampoules
7.6. Others
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Generic*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Branded
8.4. Biologic
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Biopharmaceutical companies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Biotechnology companies
9.4. Research Organizations
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Gerresheimer AG
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Stevanato Group.
12.3. NIPRO Corporation.
12.4. SGD SA.
12.5. Alphial S.r.l.
12.6. Bormioli Pharma S.p.A.
12.7. Ardagh Group
12.8. Beatson Clark
12.9. Vitro SAB
12.10. Stoelzle Glass Group.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us